A detailed history of Geode Capital Management, LLC transactions in Sera Prognostics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 586,837 shares of SERA stock, worth $4.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
586,837
Previous 538,868 8.9%
Holding current value
$4.8 Million
Previous $3.19 Million 43.48%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.29 - $8.43 $253,756 - $404,378
47,969 Added 8.9%
586,837 $4.58 Million
Q2 2024

Aug 09, 2024

BUY
$5.6 - $11.69 $1.85 Million - $3.87 Million
331,090 Added 159.35%
538,868 $3.19 Million
Q1 2024

May 13, 2024

BUY
$5.05 - $10.0 $26,174 - $51,830
5,183 Added 2.56%
207,778 $1.89 Million
Q4 2023

Feb 13, 2024

BUY
$1.65 - $6.85 $40,103 - $166,489
24,305 Added 13.63%
202,595 $1.21 Million
Q3 2023

Nov 13, 2023

BUY
$1.55 - $3.34 $50,846 - $109,565
32,804 Added 22.55%
178,290 $331,000
Q1 2023

May 15, 2023

BUY
$1.19 - $4.25 $26,083 - $93,155
21,919 Added 17.74%
145,486 $557,000
Q4 2022

Feb 13, 2023

SELL
$1.16 - $1.8 $323 - $502
-279 Reduced 0.23%
123,567 $151,000
Q3 2022

Nov 14, 2022

BUY
$1.55 - $2.71 $146,972 - $256,964
94,821 Added 326.69%
123,846 $198,000
Q2 2022

Aug 12, 2022

SELL
$1.2 - $3.62 $74,652 - $225,200
-62,210 Reduced 68.19%
29,025 $47,000
Q1 2022

May 13, 2022

BUY
$2.96 - $8.8 $88,811 - $264,035
30,004 Added 49.0%
91,235 $345,000
Q4 2021

Feb 11, 2022

BUY
$6.87 - $11.41 $63,629 - $105,679
9,262 Added 17.82%
61,231 $420,000
Q3 2021

Nov 12, 2021

BUY
$7.9 - $13.04 $410,555 - $677,675
51,969 New
51,969 $577,000

Others Institutions Holding SERA

About SERA PROGNOSTICS, INC.


  • Ticker SERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 29,596,900
  • Market Cap $242M
  • Description
  • Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product ...
More about SERA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.